Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.
Showing fund managers & funds registered for sale globally. You can filter by individual jurisdictions.

Funds & Fund Managers

All calculations in USD, unless stated
over :
 Average Manager Total Return : 15.7% (31 March 2016 - 31 March 2017)
Total Return
1 of 33

32.3%

2 of 33

30.1%

3 of 33

27.0%

4 of 33

26.0%

4 of 33

26.0%

6 of 33

22.8%

6 of 33

22.8%

8 of 33

22.4%

9 of 33

20.7%

10 of 33

20.3%

11 of 33

19.6%

12 of 33

19.3%

13 of 33

19.2%

14 of 33

18.7%

15 of 33

17.8%

16 of 33

17.6%

17 of 33

16.7%

17 of 33

16.7%

19 of 33

16.0%

20 of 33

14.3%

21 of 33

12.8%

22 of 33

12.7%

23 of 33

12.6%

24 of 33

12.4%

25 of 33

11.9%

26 of 33

10.0%

26 of 33

10.0%

28 of 33

6.5%

29 of 33

6.2%

30 of 33

3.5%

31 of 33

1.8%

32 of 33

1.3%

33 of 33

-8.3%

Managers with less than 12 months history are below. View 1 month performance
Show more managers
Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated). Portions of the information contained on this page was derived by Citywire Financial Publishers Ltd using content supplied by Lipper, A Reuters Company.

Pfizer power play: healthcare stars react to $14bn deal

Citywire Selector canvassed sector specialists on what the pharma giant’s latest purchase means for M&A and long-term investments.

The freedom five: managers choose their top US stocks

As the United States celebrates 240 years of independence from British rule, Citywire Selector looks at top firms in the country

Franklin Templeton boosts blockbuster biotech team

US giant assigns third person to oversee dedicated equity investment vehicle, Citywire Selector learns.

Swiss boutique group launches biotech fund

Following Pictet's mandate withdrawal, Sectoral AM announces the launch of a new dedicated fund.

Politics will not 'kill the golden goose', says biotech specialist

Franklin Templeton's Evan McCulloch is braced for potential disruption from Presidential race but believes idiosyncratic stories can stand up to the task.

Pictet drops veteran to take $1.2bn biotech fund in-house

Swiss group ends working relationship with manager who had overseen dedicated strategy for past 20 years.